/
Oncology
Malignancies
241
Pipeline Programs↗
264
Active Trials↗
210
Companies Involved↗
Malignancies is a highly competitive landscape with 241 programs across 210 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Institut de Recherches Internationales Servier, AstraZeneca. 21 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical33
Phase 1110
Phase 277
Phase 321
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
164 of 216 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 216 classified programs, each share of the total. Modality classified for 97% of 241 pipeline programs.
Analysis
Trial Status
1,076
clinical trials
Completed471 · 44%
Terminated187 · 17%
Recruiting171 · 16%
Unknown status95 · 9%
Withdrawn47 · 4%
Active, not recruiting45 · 4%
Other60 · 6%
Clinical Trials
Trial Activity
1076 trials
Page 1 of 72
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)